Literature DB >> 24876152

The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: antiangiogenic implications in pancreatic cancer.

Mishaal B Patel1, Srinivasa P Pothula1, Zhihong Xu1, Alexandra K Lee1, David Goldstein1, Romano C Pirola1, Minoti V Apte2, Jeremy S Wilson1.   

Abstract

Activated cancer-associated human pancreatic stellate cells (CAhPSCs, which produce the collagenous stroma of pancreatic cancer [PC]) are known to play a major role in PC progression. Apart from inducing cancer cell proliferation and migration, CAhPSCs have also been implicated in neoangiogenesis in PC. However, the mechanisms mediating the observed angiogenic effects of CAhPSCs are unknown. A candidate pathway that may be involved in this process is the hepatocyte growth factor (HGF)/c-MET pathway and its helper molecule, urokinase-type plasminogen activator (uPA). This study investigated the effects of CAhPSC secretions on endothelial cell function in the presence and absence of HGF, c-MET and uPA inhibitors. HGF levels in CAhPSC secretions were quantified using ELISA. CAhPSC secretions were then incubated with human microvascular endothelial cells (HMEC-1) and angiogenesis assessed by quantifying HMEC-1 tube formation and proliferation. CAhPSC-secreted HGF significantly increased HMEC-1 tube formation and proliferation; notably, these effects were downregulated by inhibition of HGF, its receptor c-MET and uPA. Phosphorylation of p38 mitogen-activated protein kinase was downregulated during inhibition of the HGF/c-MET pathway, whereas phosphatidylinositol-3 kinase and ERK1/2 remained unaffected. Our studies have shown for the first time that CAhPSCs induce proliferation and tube formation of HMEC-1 and that the HGF/c-MET pathway plays a major role in this induction. Given that standard antiangiogenic treatment targeting vascular endothelial growth factor has had limited success in the clinical setting, the findings of the current study provide strong support for a novel, alternative antiangiogenic approach targeting the HGF/c-MET and uPA pathways in PC.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24876152     DOI: 10.1093/carcin/bgu122

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  29 in total

1.  Response.

Authors:  David Goldstein; Daniel Von Hoff
Journal:  J Natl Cancer Inst       Date:  2015-08-06       Impact factor: 13.506

2.  Heterogeneous Stromal Signaling within the Tumor Microenvironment Controls the Metastasis of Pancreatic Cancer.

Authors:  Agnieszka A Rucki; Kelly Foley; Pingbo Zhang; Qian Xiao; Jennifer Kleponis; Annie A Wu; Rajni Sharma; Guanglan Mo; Angen Liu; Jennifer Van Eyk; Elizabeth M Jaffee; Lei Zheng
Journal:  Cancer Res       Date:  2016-11-07       Impact factor: 12.701

Review 3.  The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities.

Authors:  Anteneh A Tesfaye; Mandana Kamgar; Asfar Azmi; Philip A Philip
Journal:  Expert Rev Anticancer Ther       Date:  2017-12-19       Impact factor: 4.512

Review 4.  Pancreatic stellate cells - rising stars in pancreatic pathologies.

Authors:  P Hrabák; M Kalousová; T Krechler; T Zima
Journal:  Physiol Res       Date:  2021-12-30       Impact factor: 2.139

5.  PF-2341066 combined with celecoxib promotes apoptosis and inhibits proliferation in human cholangiocarcinoma QBC939 cells.

Authors:  Chen Chen; Dinghua Yang; Qinghua Zeng; Liang Luo; Chengzhi Cai
Journal:  Exp Ther Med       Date:  2018-03-20       Impact factor: 2.447

Review 6.  FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer.

Authors:  Chiara Caparello; Laura L Meijer; Ingrid Garajova; Alfredo Falcone; Tessa Y Le Large; Niccola Funel; Geert Kazemier; Godefridus J Peters; Enrico Vasile; Elisa Giovannetti
Journal:  World J Gastroenterol       Date:  2016-08-21       Impact factor: 5.742

7.  Nicotine Reduces Survival via Augmentation of Paracrine HGF-MET Signaling in the Pancreatic Cancer Microenvironment.

Authors:  Daniel Delitto; Dongyu Zhang; Song Han; Brian S Black; Andrea E Knowlton; Adrian C Vlada; George A Sarosi; Kevin E Behrns; Ryan M Thomas; Xiaomin Lu; Chen Liu; Thomas J George; Steven J Hughes; Shannon M Wallet; Jose G Trevino
Journal:  Clin Cancer Res       Date:  2015-12-14       Impact factor: 12.531

8.  Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer.

Authors:  Matteo Ligorio; Srinjoy Sil; Jose Malagon-Lopez; Linda T Nieman; Sandra Misale; Mauro Di Pilato; Richard Y Ebright; Murat N Karabacak; Anupriya S Kulkarni; Ann Liu; Nicole Vincent Jordan; Joseph W Franses; Julia Philipp; Johannes Kreuzer; Niyati Desai; Kshitij S Arora; Mihir Rajurkar; Elad Horwitz; Azfar Neyaz; Eric Tai; Neelima K C Magnus; Kevin D Vo; Chittampalli N Yashaswini; Francesco Marangoni; Myriam Boukhali; Jackson P Fatherree; Leah J Damon; Kristina Xega; Rushil Desai; Melissa Choz; Francesca Bersani; Adam Langenbucher; Vishal Thapar; Robert Morris; Ulrich F Wellner; Oliver Schilling; Michael S Lawrence; Andrew S Liss; Miguel N Rivera; Vikram Deshpande; Cyril H Benes; Shyamala Maheswaran; Daniel A Haber; Carlos Fernandez-Del-Castillo; Cristina R Ferrone; Wilhelm Haas; Martin J Aryee; David T Ting
Journal:  Cell       Date:  2019-05-30       Impact factor: 41.582

9.  Novel nanopolymer RNA therapeutics normalize human diabetic corneal wound healing and epithelial stem cells.

Authors:  Andrei A Kramerov; Ruchi Shah; Hui Ding; Eggehard Holler; Sue Turjman; Yaron S Rabinowitz; Sean Ghiam; Ezra Maguen; Clive N Svendsen; Mehrnoosh Saghizadeh; Julia Y Ljubimova; Alexander V Ljubimov
Journal:  Nanomedicine       Date:  2020-11-10       Impact factor: 5.307

Review 10.  Hepatocyte Growth Factor from a Clinical Perspective: A Pancreatic Cancer Challenge.

Authors:  Wasia Rizwani; Amanda E Allen; Jose G Trevino
Journal:  Cancers (Basel)       Date:  2015-09-03       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.